Dicerna Pharma (DRNA) Misses Q3 EPS by 23c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ANT
4. FFAI
5. FFR
6. LLY
7. TSLA
8. META
9. FICO
10. CART

Go back to Dicerna Pharma (DRNA) Misses Q3 EPS by 23c

Dicerna Pharmaceuticals (DRNA) PT Raised to $10 at H.C. Wainwright on 3Q Report; 'Landmark Deal With BI on NASH Target Validates GalXC Platform'

November 3, 2017 7:53 AM EDT

H.C. Wainwright raised its price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $10.00 (from $6.00) while maintaining a Buy rating, following news of a research collaboration and license agreement, as the company reported third quarter earnings report.

Analyst Ed Arce notes a positive outlook... More